ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients … – Business Wire (press release)
ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients …Business Wire (press release)SEATTLE–(BUSINESS WIRE)–The Alliance for Children's Therapeutics (ACT), a pediatric research collaboration between Seattle Children's Research Institute and biotech company Kineta Inc. Whose goal is to speed development of new medications for …and more »
[monetize id=”1″] [monetize id=”2″]
Novartis highlights strong innovation momentum at its second Meet Novartis … – Nasdaq
Novartis highlights strong innovation momentum at its second Meet Novartis …NasdaqIn Pharmaceuticals, we have a deep portfolio with Entresto (LCZ696) for chronic heart failure, Cosentyx for psoriasis, our newly acquired Oncology assets, and a strategy to lead in second generation immuno-oncology. … The combination was granted …and more »
https://www.dpsw.org/treatment-for-psoria…
